Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L21 pseudogene 97 (RPL21P97) is classified as a processed pseudogene in the human genome[1][4][5][11]. Pseudogenes are DNA sequences similar to functional genes but typically lack the ability to encode functional proteins due to mutations or loss of regulatory elements[5][6]. RPL21P97 is derived from the ancestral ribosomal protein L21 gene, but, unlike the protein-coding RPL21 gene, it does not produce a functional ribosomal protein and is not implicated in any known biological processes, pathways, or diseases. There are no known drugs or therapies that interact with, or act through, this pseudogene. Key distinctions: - The protein-coding RPL21 gene (not RPL21P97) encodes a component of the 60S ribosomal subunit and is associated with protein synthesis and some genetic diseases, but pseudogenes like RPL21P97 do not share these characteristics[7][10][13]. - RPL21P97 is not a therapeutic target, gene product, or biomarker candidate, and is included in genetic databases mainly for genome annotation purposes[5][11]. This entry is specific and accurate based on available genetic and biological data.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 97 (RPL21P97).